Loading…
Novel promising benzoxazole/benzothiazole‐derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis
Eleven novel benzoxazole/benzothiazole‐based thalidomide analogs were designed and synthesized to obtain new effective antitumor immunomodulatory agents. The synthesized compounds were evaluated for their cytotoxic activities against HepG‐2, HCT‐116, PC3, and MCF‐7 cells. Generally, the open analogs...
Saved in:
Published in: | Archiv der Pharmazie (Weinheim) 2023-09, Vol.356 (9), p.e2300097-n/a |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3737-61913a1a58dd16c585b052a115846864307da40ddc1780cb80bc07f0f849bc293 |
---|---|
cites | cdi_FETCH-LOGICAL-c3737-61913a1a58dd16c585b052a115846864307da40ddc1780cb80bc07f0f849bc293 |
container_end_page | n/a |
container_issue | 9 |
container_start_page | e2300097 |
container_title | Archiv der Pharmazie (Weinheim) |
container_volume | 356 |
creator | Elkady, Hazem El‐Adl, Khaled Sakr, Helmy Abdelraheem, Adel S. Eissa, Sally I. El‐Zahabi, Mohamed Ayman |
description | Eleven novel benzoxazole/benzothiazole‐based thalidomide analogs were designed and synthesized to obtain new effective antitumor immunomodulatory agents. The synthesized compounds were evaluated for their cytotoxic activities against HepG‐2, HCT‐116, PC3, and MCF‐7 cells. Generally, the open analogs with semicarbazide and thiosemicarbazide moieties (10, 13a–c, 14, and 17a,b) exhibited higher cytotoxic activities than derivatives with closed glutarimide moiety (8a–d). In particular, compound 13a (IC50 = 6.14, 5.79, 10.26, and 4.71 µM against HepG‐2, HCT‐116, PC3, and MCF‐7, respectively) and 14 (IC50 = 7.93, 8.23, 12.37, and 5.43 µM, respectively) exhibited the highest anticancer activities against the four tested cell lines. The most active compounds 13a and 14 were further evaluated for their in vitro immunomodulatory activities on tumor necrosis factor‐alpha (TNF‐α), caspase‐8 (CASP8), vascular endothelial growth factor (VEGF), and nuclear factor kappa‐B p65 (NF‐κB p65) in HCT‐116 cells. Compounds 13a and 14 showed a remarkable and significant reduction in TNF‐α. Furthermore, they showed significant elevation in CASP8 levels. Also, they significantly inhibited VEGF. In addition, compound 13a showed significant decreases in the level of NF‐κB p65 while compound 14 demonstrated an insignificant decrease with respect to thalidomide. Moreover, our derivatives exhibited good in silico absorption, distribution, metabolism, elimination, toxicity (ADMET) profiles.
Eleven benzoxazole/benzothiazole‐based thalidomide analogs were designed and synthesized. In vitro cytotoxic activities were evaluated against four human cell lines: MCF‐7, HCT‐116, HepG‐2, and PC3. In vitro immunomodulatory assays on tumor necrosis factor‐alpha and studies on the effects on human caspase 3 levels, vascular endothelial growth factor inhibition, and on nuclear factor kappa‐B p65 were carried out for 13a and 14. |
doi_str_mv | 10.1002/ardp.202300097 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2831296862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2859614848</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3737-61913a1a58dd16c585b052a115846864307da40ddc1780cb80bc07f0f849bc293</originalsourceid><addsrcrecordid>eNqFkc1u1DAURi1ERYfCliWyxIZFM_Vv4rAbdQpUagGhso4c2zN15diDnUybrngEJN6QJ6nTKUViw8rXV-ceXfsD4BVGc4wQOZJRb-YEEYoQqqsnYIY5wQXDgj0FM0RLXpSE0n3wPKWrjFBE-DOwTyta1YShGfj1KWyNg5sYOpusX8PW-NtwI2-DM0f3dX9p72-_f_zUJtqt0dB23eBDF_TgZB_iCOXa-D69g0uT7NofwjT6_jLX6RBK31slvTIRmq10g-xt8FM7azxM1lkV4GJ5fnKRe9KNeegF2FtJl8zLh_MAfHt_cnH8sTj7_OH0eHFWqGn_osQ1phJLLrTGpeKCt4gTiTEXrBQlo6jSkiGtFa4EUq1ArULVCq0Eq1tFanoA3u68-fXfB5P6Jv-BMs5Jb8KQGiIoJnVWkYy--Qe9CkPM-04Ur0vMBBOZmu8oFUNK0ayaTbSdjGODUTPF1UxxNY9x5YHXD9qh7Yx-xP_kk4F6B1xbZ8b_6JrF1-WXv_I7Hvykcw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2859614848</pqid></control><display><type>article</type><title>Novel promising benzoxazole/benzothiazole‐derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis</title><source>Wiley</source><creator>Elkady, Hazem ; El‐Adl, Khaled ; Sakr, Helmy ; Abdelraheem, Adel S. ; Eissa, Sally I. ; El‐Zahabi, Mohamed Ayman</creator><creatorcontrib>Elkady, Hazem ; El‐Adl, Khaled ; Sakr, Helmy ; Abdelraheem, Adel S. ; Eissa, Sally I. ; El‐Zahabi, Mohamed Ayman</creatorcontrib><description>Eleven novel benzoxazole/benzothiazole‐based thalidomide analogs were designed and synthesized to obtain new effective antitumor immunomodulatory agents. The synthesized compounds were evaluated for their cytotoxic activities against HepG‐2, HCT‐116, PC3, and MCF‐7 cells. Generally, the open analogs with semicarbazide and thiosemicarbazide moieties (10, 13a–c, 14, and 17a,b) exhibited higher cytotoxic activities than derivatives with closed glutarimide moiety (8a–d). In particular, compound 13a (IC50 = 6.14, 5.79, 10.26, and 4.71 µM against HepG‐2, HCT‐116, PC3, and MCF‐7, respectively) and 14 (IC50 = 7.93, 8.23, 12.37, and 5.43 µM, respectively) exhibited the highest anticancer activities against the four tested cell lines. The most active compounds 13a and 14 were further evaluated for their in vitro immunomodulatory activities on tumor necrosis factor‐alpha (TNF‐α), caspase‐8 (CASP8), vascular endothelial growth factor (VEGF), and nuclear factor kappa‐B p65 (NF‐κB p65) in HCT‐116 cells. Compounds 13a and 14 showed a remarkable and significant reduction in TNF‐α. Furthermore, they showed significant elevation in CASP8 levels. Also, they significantly inhibited VEGF. In addition, compound 13a showed significant decreases in the level of NF‐κB p65 while compound 14 demonstrated an insignificant decrease with respect to thalidomide. Moreover, our derivatives exhibited good in silico absorption, distribution, metabolism, elimination, toxicity (ADMET) profiles.
Eleven benzoxazole/benzothiazole‐based thalidomide analogs were designed and synthesized. In vitro cytotoxic activities were evaluated against four human cell lines: MCF‐7, HCT‐116, HepG‐2, and PC3. In vitro immunomodulatory assays on tumor necrosis factor‐alpha and studies on the effects on human caspase 3 levels, vascular endothelial growth factor inhibition, and on nuclear factor kappa‐B p65 were carried out for 13a and 14.</description><identifier>ISSN: 0365-6233</identifier><identifier>EISSN: 1521-4184</identifier><identifier>DOI: 10.1002/ardp.202300097</identifier><identifier>PMID: 37379240</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>anticancer ; benzoxazole/benzothiazole derivatives ; Cancer ; Cytotoxicity ; immunomodulators ; thalidomide analogs ; Tumor necrosis factor-TNF ; Vascular endothelial growth factor</subject><ispartof>Archiv der Pharmazie (Weinheim), 2023-09, Vol.356 (9), p.e2300097-n/a</ispartof><rights>2023 Deutsche Pharmazeutische Gesellschaft.</rights><rights>2023 Deutsche Pharmazeutische Gesellschaft</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3737-61913a1a58dd16c585b052a115846864307da40ddc1780cb80bc07f0f849bc293</citedby><cites>FETCH-LOGICAL-c3737-61913a1a58dd16c585b052a115846864307da40ddc1780cb80bc07f0f849bc293</cites><orcidid>0000-0003-0893-6703 ; 0000-0002-8922-9770 ; 0000-0003-4538-5840</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37379240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elkady, Hazem</creatorcontrib><creatorcontrib>El‐Adl, Khaled</creatorcontrib><creatorcontrib>Sakr, Helmy</creatorcontrib><creatorcontrib>Abdelraheem, Adel S.</creatorcontrib><creatorcontrib>Eissa, Sally I.</creatorcontrib><creatorcontrib>El‐Zahabi, Mohamed Ayman</creatorcontrib><title>Novel promising benzoxazole/benzothiazole‐derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis</title><title>Archiv der Pharmazie (Weinheim)</title><addtitle>Arch Pharm (Weinheim)</addtitle><description>Eleven novel benzoxazole/benzothiazole‐based thalidomide analogs were designed and synthesized to obtain new effective antitumor immunomodulatory agents. The synthesized compounds were evaluated for their cytotoxic activities against HepG‐2, HCT‐116, PC3, and MCF‐7 cells. Generally, the open analogs with semicarbazide and thiosemicarbazide moieties (10, 13a–c, 14, and 17a,b) exhibited higher cytotoxic activities than derivatives with closed glutarimide moiety (8a–d). In particular, compound 13a (IC50 = 6.14, 5.79, 10.26, and 4.71 µM against HepG‐2, HCT‐116, PC3, and MCF‐7, respectively) and 14 (IC50 = 7.93, 8.23, 12.37, and 5.43 µM, respectively) exhibited the highest anticancer activities against the four tested cell lines. The most active compounds 13a and 14 were further evaluated for their in vitro immunomodulatory activities on tumor necrosis factor‐alpha (TNF‐α), caspase‐8 (CASP8), vascular endothelial growth factor (VEGF), and nuclear factor kappa‐B p65 (NF‐κB p65) in HCT‐116 cells. Compounds 13a and 14 showed a remarkable and significant reduction in TNF‐α. Furthermore, they showed significant elevation in CASP8 levels. Also, they significantly inhibited VEGF. In addition, compound 13a showed significant decreases in the level of NF‐κB p65 while compound 14 demonstrated an insignificant decrease with respect to thalidomide. Moreover, our derivatives exhibited good in silico absorption, distribution, metabolism, elimination, toxicity (ADMET) profiles.
Eleven benzoxazole/benzothiazole‐based thalidomide analogs were designed and synthesized. In vitro cytotoxic activities were evaluated against four human cell lines: MCF‐7, HCT‐116, HepG‐2, and PC3. In vitro immunomodulatory assays on tumor necrosis factor‐alpha and studies on the effects on human caspase 3 levels, vascular endothelial growth factor inhibition, and on nuclear factor kappa‐B p65 were carried out for 13a and 14.</description><subject>anticancer</subject><subject>benzoxazole/benzothiazole derivatives</subject><subject>Cancer</subject><subject>Cytotoxicity</subject><subject>immunomodulators</subject><subject>thalidomide analogs</subject><subject>Tumor necrosis factor-TNF</subject><subject>Vascular endothelial growth factor</subject><issn>0365-6233</issn><issn>1521-4184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkc1u1DAURi1ERYfCliWyxIZFM_Vv4rAbdQpUagGhso4c2zN15diDnUybrngEJN6QJ6nTKUViw8rXV-ceXfsD4BVGc4wQOZJRb-YEEYoQqqsnYIY5wQXDgj0FM0RLXpSE0n3wPKWrjFBE-DOwTyta1YShGfj1KWyNg5sYOpusX8PW-NtwI2-DM0f3dX9p72-_f_zUJtqt0dB23eBDF_TgZB_iCOXa-D69g0uT7NofwjT6_jLX6RBK31slvTIRmq10g-xt8FM7azxM1lkV4GJ5fnKRe9KNeegF2FtJl8zLh_MAfHt_cnH8sTj7_OH0eHFWqGn_osQ1phJLLrTGpeKCt4gTiTEXrBQlo6jSkiGtFa4EUq1ArULVCq0Eq1tFanoA3u68-fXfB5P6Jv-BMs5Jb8KQGiIoJnVWkYy--Qe9CkPM-04Ur0vMBBOZmu8oFUNK0ayaTbSdjGODUTPF1UxxNY9x5YHXD9qh7Yx-xP_kk4F6B1xbZ8b_6JrF1-WXv_I7Hvykcw</recordid><startdate>202309</startdate><enddate>202309</enddate><creator>Elkady, Hazem</creator><creator>El‐Adl, Khaled</creator><creator>Sakr, Helmy</creator><creator>Abdelraheem, Adel S.</creator><creator>Eissa, Sally I.</creator><creator>El‐Zahabi, Mohamed Ayman</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0893-6703</orcidid><orcidid>https://orcid.org/0000-0002-8922-9770</orcidid><orcidid>https://orcid.org/0000-0003-4538-5840</orcidid></search><sort><creationdate>202309</creationdate><title>Novel promising benzoxazole/benzothiazole‐derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis</title><author>Elkady, Hazem ; El‐Adl, Khaled ; Sakr, Helmy ; Abdelraheem, Adel S. ; Eissa, Sally I. ; El‐Zahabi, Mohamed Ayman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3737-61913a1a58dd16c585b052a115846864307da40ddc1780cb80bc07f0f849bc293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>anticancer</topic><topic>benzoxazole/benzothiazole derivatives</topic><topic>Cancer</topic><topic>Cytotoxicity</topic><topic>immunomodulators</topic><topic>thalidomide analogs</topic><topic>Tumor necrosis factor-TNF</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elkady, Hazem</creatorcontrib><creatorcontrib>El‐Adl, Khaled</creatorcontrib><creatorcontrib>Sakr, Helmy</creatorcontrib><creatorcontrib>Abdelraheem, Adel S.</creatorcontrib><creatorcontrib>Eissa, Sally I.</creatorcontrib><creatorcontrib>El‐Zahabi, Mohamed Ayman</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Archiv der Pharmazie (Weinheim)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elkady, Hazem</au><au>El‐Adl, Khaled</au><au>Sakr, Helmy</au><au>Abdelraheem, Adel S.</au><au>Eissa, Sally I.</au><au>El‐Zahabi, Mohamed Ayman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel promising benzoxazole/benzothiazole‐derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis</atitle><jtitle>Archiv der Pharmazie (Weinheim)</jtitle><addtitle>Arch Pharm (Weinheim)</addtitle><date>2023-09</date><risdate>2023</risdate><volume>356</volume><issue>9</issue><spage>e2300097</spage><epage>n/a</epage><pages>e2300097-n/a</pages><issn>0365-6233</issn><eissn>1521-4184</eissn><abstract>Eleven novel benzoxazole/benzothiazole‐based thalidomide analogs were designed and synthesized to obtain new effective antitumor immunomodulatory agents. The synthesized compounds were evaluated for their cytotoxic activities against HepG‐2, HCT‐116, PC3, and MCF‐7 cells. Generally, the open analogs with semicarbazide and thiosemicarbazide moieties (10, 13a–c, 14, and 17a,b) exhibited higher cytotoxic activities than derivatives with closed glutarimide moiety (8a–d). In particular, compound 13a (IC50 = 6.14, 5.79, 10.26, and 4.71 µM against HepG‐2, HCT‐116, PC3, and MCF‐7, respectively) and 14 (IC50 = 7.93, 8.23, 12.37, and 5.43 µM, respectively) exhibited the highest anticancer activities against the four tested cell lines. The most active compounds 13a and 14 were further evaluated for their in vitro immunomodulatory activities on tumor necrosis factor‐alpha (TNF‐α), caspase‐8 (CASP8), vascular endothelial growth factor (VEGF), and nuclear factor kappa‐B p65 (NF‐κB p65) in HCT‐116 cells. Compounds 13a and 14 showed a remarkable and significant reduction in TNF‐α. Furthermore, they showed significant elevation in CASP8 levels. Also, they significantly inhibited VEGF. In addition, compound 13a showed significant decreases in the level of NF‐κB p65 while compound 14 demonstrated an insignificant decrease with respect to thalidomide. Moreover, our derivatives exhibited good in silico absorption, distribution, metabolism, elimination, toxicity (ADMET) profiles.
Eleven benzoxazole/benzothiazole‐based thalidomide analogs were designed and synthesized. In vitro cytotoxic activities were evaluated against four human cell lines: MCF‐7, HCT‐116, HepG‐2, and PC3. In vitro immunomodulatory assays on tumor necrosis factor‐alpha and studies on the effects on human caspase 3 levels, vascular endothelial growth factor inhibition, and on nuclear factor kappa‐B p65 were carried out for 13a and 14.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37379240</pmid><doi>10.1002/ardp.202300097</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0003-0893-6703</orcidid><orcidid>https://orcid.org/0000-0002-8922-9770</orcidid><orcidid>https://orcid.org/0000-0003-4538-5840</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0365-6233 |
ispartof | Archiv der Pharmazie (Weinheim), 2023-09, Vol.356 (9), p.e2300097-n/a |
issn | 0365-6233 1521-4184 |
language | eng |
recordid | cdi_proquest_miscellaneous_2831296862 |
source | Wiley |
subjects | anticancer benzoxazole/benzothiazole derivatives Cancer Cytotoxicity immunomodulators thalidomide analogs Tumor necrosis factor-TNF Vascular endothelial growth factor |
title | Novel promising benzoxazole/benzothiazole‐derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T19%3A04%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20promising%20benzoxazole/benzothiazole%E2%80%90derived%20immunomodulatory%20agents:%20Design,%20synthesis,%20anticancer%20evaluation,%20and%20in%20silico%20ADMET%20analysis&rft.jtitle=Archiv%20der%20Pharmazie%20(Weinheim)&rft.au=Elkady,%20Hazem&rft.date=2023-09&rft.volume=356&rft.issue=9&rft.spage=e2300097&rft.epage=n/a&rft.pages=e2300097-n/a&rft.issn=0365-6233&rft.eissn=1521-4184&rft_id=info:doi/10.1002/ardp.202300097&rft_dat=%3Cproquest_cross%3E2859614848%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3737-61913a1a58dd16c585b052a115846864307da40ddc1780cb80bc07f0f849bc293%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2859614848&rft_id=info:pmid/37379240&rfr_iscdi=true |